The closing price of SELLAS Life Sciences Group Inc (NASDAQ: SLS) was $1.40 for the day, down -3.11% from the previous closing price of $1.45. In other words, the price has decreased by -$0.0450 from its previous closing price. On the day, 2203658 shares were traded.
Ratios:
Our analysis of SLS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.23 and its Current Ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 21, 2021, initiated with a Overweight rating and assigned the stock a target price of $18.
On April 02, 2018, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $11.H.C. Wainwright initiated its Buy rating on April 02, 2018, with a $11 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLS now has a Market Capitalization of 78.77M and an Enterprise Value of 77.15M. Its current Enterprise Value per Revenue stands at 20.84 whereas that against EBITDA is -2.04.
Stock Price History:
Over the past 52 weeks, SLS has reached a high of $1.91, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is 0.9992, while the 200-Day Moving Average is calculated to be 1.1878.
Shares Statistics:
SLS traded an average of 1.44M shares per day over the past three months and 2.08M shares per day over the past ten days. A total of 56.27M shares are outstanding, with a floating share count of 55.75M. Insiders hold about 0.92% of the company’s shares, while institutions hold 9.91% stake in the company. Shares short for SLS as of Mar 15, 2024 were 5.18M with a Short Ratio of 3.61, compared to 3.89M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.73% and a Short% of Float of 11.75%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.16 and a low estimate of -$0.25, while EPS last year was -$0.47. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.16 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$0.6 and -$1.15 for the fiscal current year, implying an average EPS of -$0.87. EPS for the following year is -$0.85, with 4 analysts recommending between -$0.5 and -$1.28.
